

Date: 10<sup>th</sup> February, 2024

To,  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 511523

**Sub.: Unaudited Financial Results for the quarter and nine months ended December 31, 2023**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing Unaudited Financial Results for the quarter and nine months ended December 31, 2023.
2. Limited Review Report on Unaudited Financial Results for the quarter and nine months ended December 31, 2023.

Thanking You.

Yours faithfully,  
For **Veerhealth Care Limited**

Bhavin S. Shah  
Managing Director  
DIN: 03129574



Encl: As above

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 31-12-2023	Quarter ended 30-09-2023	Quarter ended 31-12-2022	Nine Months ended 31-12-2023	Nine Months ended 31-12-2022	Year ended 31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	286.91	382.79	275.45	1027.83	953.92	1327.33
II	Other Income	24.10	41.51	35.19	80.12	96.44	123.94
III	<b>Total Revenue (I + II)</b>	<b>311.01</b>	<b>424.30</b>	<b>310.64</b>	<b>1107.95</b>	<b>1050.36</b>	<b>1451.27</b>
IV	<b>Expenses:</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	79.67	291.08	246.01	565.17	710.80	971.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	114.48	-34.58	-59.05	115.11	-45.99	-48.17
	(d) Employee benefits expense	28.65	30.61	27.18	87.45	69.28	90.19
	(e) Finance Costs	0.36	0.16	0.06	0.54	0.09	0.12
	(f) Depreciation and amortisation expense	17.89	17.56	15.82	53.00	45.99	62.18
	(g) Other expenses	46.29	74.22	44.87	177.53	204.64	264.10
	<b>Total Expenses</b>	<b>287.34</b>	<b>379.05</b>	<b>274.89</b>	<b>998.80</b>	<b>984.81</b>	<b>1339.58</b>
V	<b>Profit/(Loss) before exceptional items (III - IV)</b>	<b>23.67</b>	<b>45.25</b>	<b>35.75</b>	<b>109.15</b>	<b>65.55</b>	<b>111.69</b>
VI	Exceptional items	0.16	0.00	0.00	0.16	0.00	0.00
VII	<b>Profit before tax (V - VI)</b>	<b>23.51</b>	<b>45.25</b>	<b>35.75</b>	<b>108.99</b>	<b>65.55</b>	<b>111.69</b>
VIII	<b>Tax expense:</b>						
	1) Current Tax	4.35	6.00	2.65	16.35	9.15	19.65
	2) Prior Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Deferred Tax	0.00	0.00	0.15	0.00	0.44	-66.16
IX	<b>Profit/(Loss) for the period (VII - VIII)</b>	<b>19.16</b>	<b>39.25</b>	<b>32.95</b>	<b>92.64</b>	<b>55.96</b>	<b>158.20</b>
X	<b>Other Comprehensive Income</b>						
	(a) Items that will not be reclassified to Profit or Loss	-1.11	-1.11	-0.86	-3.32	-2.59	-6.52
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other Comprehensive Income</b>	<b>-1.11</b>	<b>-1.11</b>	<b>-0.86</b>	<b>-3.32</b>	<b>-2.59</b>	<b>-6.52</b>
XI	<b>Total Comprehensive Income for the period (IX + X)</b>	<b>18.05</b>	<b>38.14</b>	<b>32.09</b>	<b>89.32</b>	<b>53.37</b>	<b>151.68</b>
XII	Paid-up equity share capital of Rs. 10 each	1999.85	1999.85	693.42	1999.85	693.42	999.92
XIII	Other Equity						1143.35
XIV	<b>Net Worth</b>						<b>2143.27</b>
XV	<b>Earnings Per Share (of Rs. 10 each):</b>						
	(a) Basic (in Rs.)	0.09	0.19	0.46	0.45	0.77	1.52
	(b) Diluted (in Rs.)	0.09	0.19	0.46	0.45	0.77	1.52

*Thangas*



**VEERHEALTH CARE LIMITED**  
Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.  
Tel. No. 022-22018582 CIN: L65910MH1992PLC067632  
Email: info@veerhealthcare.net Website: www.veerhealthcare.net

**NOTES:**

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th February, 2024. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 Rs. 0.16 Lakhs under exceptional items is loss on sale of asset.
- 3 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ('SEBI').
- 4 During the quarter ended December 31, 2023 the Company is operating in a single segment i.e. 'Healthcare Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 5 Figures of the previous periods have been rearranged / regrouped, wherever necessary.
- 6 The financial results of the Company are available at www.bseindia.com and at www.veerhealthcare.net.

Place: Mumbai  
Date: 10th February, 2024



By order of the Board  
For Veerhealth Care Limited

A handwritten signature in blue ink, appearing to read 'Bhavin S. Shah'.

Bhavin S. Shah  
Managing Director  
DIN: 03129574



**Limited Review Report**

**To the Board of Directors of Veerhealth Care Limited**

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter and year to date ended 31<sup>st</sup> December, 2023, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Jayesh R Shah & Co.**  
**Chartered Accountants**  
**Firm Regn. No.104182W**



**Jayesh Shah**  
**Proprietor**  
**Membership No.033864**



**Place: Mumbai**  
**Date: 10<sup>th</sup> February, 2024**  
**UDIN: 24033864BKEYGI3433**